Literature DB >> 1464869

Significance of plasma endothelin-1 levels in patients with systemic sclerosis.

K Yamane1, T Miyauchi, N Suzuki, T Yuhara, T Akama, H Suzuki, H Kashiwagi.   

Abstract

Endothelin-1 (ET-1) is a novel potent vasoconstrictor peptide discovered in the supernatant fraction of cultured endothelial cells. We measured plasma levels of ET-1 using a sensitive sandwich enzyme immunoassay. Plasma concentrations of ET-1 in 31 patients with systemic sclerosis (SSc) (1.90 +/- 0.47 pg/ml) were higher than those (1.31 +/- 0.10 pg/ml) in 25 age and sex matched healthy subjects. Patients with SSc with diffuse scleroderma had higher levels of ET-1 compared with those with limited scleroderma. Plasma ET-1 levels correlated inversely with carbon monoxide diffusing capacity (DLco). Measurement of plasma ET-1 levels may be useful as a predictor of prognosis of SSc.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464869

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  41 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

2.  Plasma endothelin-1 levels in Behçet's disease.

Authors:  T Uslu; C Erem; M Tosun; O Deger
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 3.  A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

Authors:  E Hachulla; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

Review 4.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 5.  [Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment].

Authors:  K Ahmadi-Simab; W L Gross
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 6.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

7.  Is macitentan not a treatment option for digital ulcers in systemic sclerosis?

Authors:  Yoshihide Asano
Journal:  Ann Transl Med       Date:  2016-10

8.  Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors.

Authors:  Xu Shi-Wen; Fernando Rodríguez-Pascual; Santiago Lamas; Alan Holmes; Sarah Howat; Jeremy D Pearson; Michael R Dashwood; Roland M du Bois; Christopher P Denton; Carol M Black; David J Abraham; Andrew Leask
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

9.  Endothelin-1 in idiopathic pulmonary fibrosis.

Authors:  M Uguccioni; L Pulsatelli; B Grigolo; A Facchini; L Fasano; C Cinti; M Fabbri; G Gasbarrini; R Meliconi
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

10.  Effectiveness of palosuran in bleomycin-induced experimental scleroderma.

Authors:  Tuncer Demir; Ibrahim Turkbeyler; Davut Sinan Kaplan; Yavuz Pehlivan; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat; Cahit Bagcı
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.